- Container
- 15 mL
- Supply period
- 30 days, as advertised
- Visit cost
- Not established as included
A more specific nasal product listing
Midi Health's Custom Rx page identifies a 15 mL NAD+ nasal spray and lists $165 for a thirty-day supply. Unlike a bare starting-price advertisement, this ties the medication charge to an explicit container and stated supply period. The information is useful for an initial budget, although the patient's actual prescription and final invoice still govern.
The page says a Midi clinician evaluates medical history and symptoms to determine whether prescribing is appropriate. Booking that visit is a separate step from reading the product listing. We have not placed an order or confirmed what any individual patient would be prescribed after that assessment.
What the bottle price lets you calculate
Dividing the listed $165 by the labeled 15 mL gives $11 per mL of supplied liquid. That is volume arithmetic only. It cannot compare the amount of NAD+ across brands without concentration information, and it says nothing about absorption or a health outcome. A less expensive milliliter is not necessarily a more useful prescription.
We do not treat the bottle price as the complete cost of care. Ask whether a visit, follow-up or shipment produces another charge and whether refills have the same terms. A thirty-day supply statement also differs from a calendar-month subscription, so obtain the actual billing and refill schedule before projecting a year of purchases.
Strength, packaging and pharmacy instructions
The reviewed listing establishes volume but does not establish a complete concentration and dispensing specification. Ask for the total NAD+ content, the pharmacy preparing the product and its labeled instructions. Do not infer the amount delivered by a spray from the bottle's volume or from another provider's preparation.
Storage and beyond-use information are especially relevant to deciding when to request a refill. The pharmacy should explain how to handle the specific dispensed product and whom to contact about a damaged shipment. A thirty-day marketing label does not override the printed beyond-use date or instructions provided with the prescription.
Interpreting the midlife energy message
Midi advertises the spray for energy and clearer thinking without a stimulant-style experience. These are intended-use and marketing descriptions from the provider. The page does not by itself demonstrate that the finished nasal formula improves those outcomes, and this review does not turn the wording into an assurance of benefit.
The fact that NAD+ participates in cellular metabolism is a starting point for research, not evidence that every person needs more of it. Studies of oral precursors and intravenous administration ask different questions from a trial of this spray. Ask the clinician what evidence is relevant to the reason they propose it for you.
How to use this review when comparing plans
Compare Midi first with other prescribed nasal products for which container details and fees are available. Record the initial visit, first bottle and expected refill cost as separate amounts. If insurance is discussed for an appointment, verify medication coverage independently instead of assuming the prescription follows the same payment rules.
The clearest published strengths are the named 15 mL package and thirty-day price basis. Remaining uncertainties include the full care bill, concentration and product-specific evidence. A clinician's recommendation and pharmacy label should resolve the practical prescription details; this review supplies questions and price context, rather than a recommendation to begin treatment.
Useful distinctions
- Labeled 15 mL container
- Defined thirty-day supply basis
- Clinical evaluation before prescribing
Limitations to weigh
- Visit charges not established as included
- No verified concentration for cross-brand quantity comparison
- No controlled trial of this finished spray verified
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.